Mycotoxin Contamination in Botanical Raw Materials: What Aflatoxin and Ochratoxin Testing Reveals About Your Herbal Supply Chain

Aflatoxin B1 is the most potent naturally occurring carcinogen the International Agency for Research on Cancer has ever classified. Group 1 — sufficient evidence of carcinogenicity in humans. At 20 parts per billion, the level at which FDA mandates action on human food, you’re talking about a quantity so vanishingly small it’s undetectable by any method except a properly equipped analytical laboratory. The problem is that standard supplier certificates of analysis almost never test for it.

If you’re manufacturing herbal supplements in Chicago, Naperville, or anywhere across the Midwest supply corridor, you’re almost certainly working with botanical raw materials that passed through tropical or subtropical growing regions — and those are exactly the conditions where mycotoxin-producing molds thrive. A lot of turmeric, milk thistle, licorice root, or valerian can arrive at your receiving dock looking and smelling perfectly normal while carrying aflatoxin levels that trigger FDA action.

The mold is often long dead by the time it reaches you. The toxin is not.

Why Botanical Raw Materials Are Uniquely Vulnerable to Mycotoxin Contamination

Unlike APIs or excipients manufactured in controlled chemical processes, botanical raw materials are agricultural products. They’re grown in open fields, harvested by hand, dried in ambient conditions, packed into burlap or polypropylene bags, and shipped across multiple continents. Every step — from field to drying yard, from regional warehouse to shipping container — creates a window for mycotoxin-producing molds to establish themselves.

The primary culprits are two genera. Aspergillus species (particularly A. flavus and A. parasiticus) produce aflatoxins B1, B2, G1, and G2. Aspergillus ochraceus and Penicillium verrucosum produce ochratoxin A (OTA). Fusarium species add fumonisins and deoxynivalenol to the mix, though those are more commonly associated with grain-based ingredients than botanical raw materials.

What makes this so difficult to catch through conventional incoming inspection is that mycotoxin production doesn’t require visible mold growth. A botanical powder can pass organoleptic review — color, odor, texture all unremarkable — while toxins from an earlier contamination event are already bound to the plant matrix. Moisture intrusion during sea freight is one of the most common triggers. A container passing through a humid tropical port, exposed to condensation, creates the water activity window that Aspergillus needs to produce toxins in as little as 24 to 48 hours. By the time that shipment reaches your Chicago-area receiving dock, the moisture has dissipated. The aflatoxin has not.

Which Botanicals Carry the Highest Mycotoxin Risk

Contamination risk isn’t uniform across botanical categories. It correlates with origin region, moisture content during processing, post-harvest handling, and the physical matrix of the ingredient. Based on published surveillance data and analytical laboratory results across the industry, several categories consistently show elevated contamination rates:

Milk thistle seed (Silybum marianum) — silymarin is concentrated in the seeds, which have a dense, lipid-rich matrix. If moisture infiltrates during storage, that matrix becomes a near-ideal substrate for aflatoxin production. Samples sourced from Eastern Europe and parts of Asia have been flagged in European Commission surveillance programs.

Licorice root (Glycyrrhiza spp.) — Root botanicals air-dried in high-humidity environments are particularly susceptible to OTA. Licorice imports from China, India, and Iran have shown detectable ochratoxin A in multiple published surveillance studies. If your licorice root COA doesn’t include OTA data, you’re missing the primary mycotoxin risk for that ingredient entirely.

Valerian root (Valeriana officinalis) — Demand has grown considerably among Midwest formulators targeting the sleep supplement market. European monitoring programs — the EU conducts far more systematic mycotoxin surveillance on botanical ingredients than FDA does domestically — show OTA in a meaningful proportion of commercial valerian samples. That data reflects the same global supply chains feeding Midwest manufacturers.

Medicinal mushrooms (reishi, chaga, lion’s mane, cordyceps) — These are fungi themselves, which means contamination with mycotoxin-producing Aspergillus species during substrate preparation, drying, or storage is a documented and underappreciated risk. The chaga market in particular is supplied largely through wild-harvest channels with essentially no testing infrastructure between the forest floor and the US importer.

Turmeric, ginger, and black pepper — High-volume Midwest supplement ingredients and well-documented high-risk categories for aflatoxins. FDA’s import surveillance data shows consistent interceptions of spice-family botanicals with mycotoxin contamination. These same ingredients already attract attention for other adulterants like lead chromate in turmeric — but mycotoxin risk in the same matrix gets far less discussion than it warrants.

A 2020 review published in the journal Toxins examining commercial herbal products found mycotoxin contamination — primarily OTA and aflatoxins — in a significant proportion of samples across multiple botanical categories. This isn’t an edge case affecting a small fraction of supply. It’s a routine supply chain reality that a systematic analytical laboratory program is designed to address.

What Your Analytical Laboratory Actually Needs to Run

Mycotoxin testing is a category of assays, not a single method. Choosing the right approach depends on your regulatory context, risk tolerance, and what decision you’re making with the result.

ELISA (enzyme-linked immunosorbent assay) is the standard screening method. Turnaround of 24–48 hours, relatively low cost per sample (typically $30–60 for a single-toxin ELISA), and detection limits well below FDA’s action levels. But ELISA is an immunoassay — antibody-antigen binding — which means cross-reactivity with structurally similar compounds can generate false positives. For high-risk materials where you need a go/no-go decision at intake, ELISA gives you a screening signal. It shouldn’t be your final word before lot release.

LC-MS/MS (liquid chromatography-tandem mass spectrometry) is the confirmatory gold standard and the method that matters when FDA is involved. A single LC-MS/MS run can simultaneously quantify aflatoxins B1, B2, G1, and G2 plus OTA, fumonisins B1 and B2, zearalenone, and deoxynivalenol with high specificity and detection limits typically in the 0.1–1 ppb range depending on the analyte and matrix. When you’re presenting data to a major retail customer, responding to an FDA inspection, or making a supplier disqualification decision, LC-MS/MS results from a qualified analytical laboratory under ISO 17025 accreditation are what you need on file.

The cost differential matters but should be kept in perspective. A full mycotoxin panel by LC-MS/MS runs approximately $150–250 per sample at most contract analytical laboratories. Stack that against the cost of a consumer complaint, a Class II recall, or a 21 CFR Part 111 observation — and the math is not close.

For most Midwest supplement brands managing 15–30 botanical SKUs, a tiered approach is practical. ELISA screening on every lot of high-risk materials. LC-MS/MS confirmation on positives, borderline ELISA results, new supplier lots, or high-volume ingredients going into core product SKUs. Full LC-MS/MS panels on any material destined for export markets governed by EU limits.

The Regulatory Framework — and Where It Gets Complicated for Midwest Brands

FDA’s human food safety regulations set 20 ppb as the action level for total aflatoxins (B1 + B2 + G1 + G2). There’s no separate action level specifically for dietary supplement raw materials — they’re covered under the same food threshold. For ochratoxin A, FDA has not established a specific action level, but the adulteration provisions of 21 USC §342 apply to any substance reasonably likely to cause harm. In practice, OTA levels above 10–20 ppb in a supplement ingredient would draw serious regulatory attention.

DSHEA’s cGMP requirements at 21 CFR Part 111 require manufacturers to establish specifications for every raw material and verify those specifications are met before use in production. The regulation doesn’t enumerate mycotoxin testing as a named requirement — but it does require a scientifically defensible basis for your raw material specifications. If FDA finds aflatoxin contamination in a finished product and your batch records show no mycotoxin screening was ever conducted, the absence of a control program becomes the observation.

California’s Proposition 65 adds complexity for any brand with distribution into the California market — which, practically speaking, means any brand with national e-commerce or major retail presence. Aflatoxin B1 is on the Prop 65 list as a carcinogen with no established safe harbor level. That doesn’t create strict liability at trace ppb concentrations, but it does mean your mycotoxin testing documentation becomes part of your California compliance posture in ways that some smaller Midwest brands haven’t anticipated.

And for brands with any international distribution, the EU limits are effectively the controlling standard regardless of your primary market. Commission Regulation (EC) No 1881/2006 caps total aflatoxins in dried herbs and spices at 5 µg/kg — one quarter of FDA’s 20 ppb threshold. OTA in spices is limited to 15 µg/kg, with tighter limits proposed in recent EFSA risk assessments. If your contract manufacturer exports, or your brand sells through any channel reaching EU consumers, you’re operating against EU limits whether or not you’ve formalized that in your specifications.

Building a Practical Mycotoxin Control Program That Actually Works

A functional program doesn’t require rebuilding your quality system. For most Midwest supplement brands, it comes down to a handful of concrete decisions made in advance rather than improvised under production pressure.

Stratify your botanical SKUs by risk. Seed botanicals, root botanicals from tropical origins, spice-family ingredients, and mushroom-derived materials belong on the high-risk tier. Botanicals sourced from well-audited domestic or Northern European suppliers with documented post-harvest controls can be assessed less frequently.

Add mycotoxin acceptance criteria to your raw material specifications. High-risk lots need mycotoxin data before they clear incoming inspection — either from ELISA screening at intake or from supplier-provided LC-MS/MS COAs from a third-party analytical laboratory with demonstrated proficiency in mycotoxin matrices.

Make supplier mycotoxin data a qualification requirement. Top-volume botanical suppliers should be providing lot-level mycotoxin COAs as part of their standard documentation package. If your current suppliers aren’t doing this, it’s a supplier qualification gap worth raising at your next annual review — and a reasonable basis for shifting volume toward suppliers who do.

Set rejection and hold criteria before you need them. Decide in advance what you do with a positive ELISA result while you await LC-MS/MS confirmation. Hold the lot; don’t release to production; document the hold and the disposition decision. These decisions belong in your SOPs, not in an ad-hoc conversation between QA and production scheduling during a busy cycle.

Maintain chain of custody for every external test. Every sample shipped to an analytical laboratory needs documented chain of custody: supplier lot number, receipt date, sample ID, shipping date, laboratory receipt confirmation, test date, results, and your internal disposition. When FDA requests raw material testing records during a 21 CFR Part 111 inspection, this is the documentation they expect to see.

The upfront cost of a systematic mycotoxin program is real but modest. The downside risk — contaminated product reaching consumers, a Class II recall, an FDA Form 483 citing inadequate raw material controls — isn’t modest at all.

---

Written by Nour Abochama, VP Operations, Qalitex | Quality Consultant, Ayah Labs. Learn more about our team

Ship your sample to our Chicago facility — get a Qalitex CoA in 5–7 days Contact us

Related from our network

• Botanical adulteration screening and identity confirmation — ISO 17025-accredited HPTLC and DNA barcoding services for herbal supplement raw material qualification
• Heavy metals and elemental impurities testing for supplement ingredients — ICP-MS testing under USP <232>/<233> for dietary supplement raw materials and finished products